Amphastar Pharmaceuticals (AMPH) Total Debt (2016 - 2025)
Historic Total Debt for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $609.5 million.
- Amphastar Pharmaceuticals' Total Debt rose 214.63% to $609.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $609.5 million, marking a year-over-year increase of 214.63%. This contributed to the annual value of $601.9 million for FY2024, which is 200.83% up from last year.
- Per Amphastar Pharmaceuticals' latest filing, its Total Debt stood at $609.5 million for Q3 2025, which was up 214.63% from $608.7 million recorded in Q2 2025.
- Amphastar Pharmaceuticals' Total Debt's 5-year high stood at $638.6 million during Q3 2023, with a 5-year trough of $38.5 million in Q2 2021.
- Over the past 5 years, Amphastar Pharmaceuticals' median Total Debt value was $501.2 million (recorded in 2023), while the average stood at $344.7 million.
- Its Total Debt has fluctuated over the past 5 years, first crashed by 1747.44% in 2021, then soared by 74374.5% in 2023.
- Amphastar Pharmaceuticals' Total Debt (Quarter) stood at $77.0 million in 2021, then decreased by 1.42% to $75.9 million in 2022, then soared by 677.51% to $590.0 million in 2023, then increased by 2.01% to $601.9 million in 2024, then grew by 1.27% to $609.5 million in 2025.
- Its Total Debt was $609.5 million in Q3 2025, compared to $608.7 million in Q2 2025 and $604.1 million in Q1 2025.